Ann: Imagion Biosystems March 2021 Investor Newsletter, page-24

We spent much of 2020 being advised that clinical trials would commence in Qtr 4.
We were advised in June 2020 that this trial would involve 15 to 20 patients.
Today the company secretary advised me it was 20 to 30 patients.
Forget the actual trial outcomes for now, how many patients have we been able to enrol at the end of qtr 1 2021?
Can you think of a reason why you wouldn't want to tell shareholders what our progress is?